117 related articles for article (PubMed ID: 2698483)
1. Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression.
Parsons B; Quitkin FM; McGrath PJ; Stewart JW; Tricamo E; Ocepek-Welikson K; Harrison W; Rabkin JG; Wager SG; Nunes E
Psychopharmacol Bull; 1989; 25(4):524-34. PubMed ID: 2698483
[TBL] [Abstract][Full Text] [Related]
2. [Impact of personality factors in depression].
Quitkin FM
Encephale; 1993 Aug; 19 Spec No 3():491-2. PubMed ID: 8299548
[TBL] [Abstract][Full Text] [Related]
3. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo.
Quitkin FM; Stewart JW; McGrath PJ; Tricamo E; Rabkin JG; Ocepek-Welikson K; Nunes E; Harrison W; Klein DF
Br J Psychiatry Suppl; 1993 Sep; (21):30-4. PubMed ID: 8217065
[TBL] [Abstract][Full Text] [Related]
4. Psychopharmacologic validation of atypical depression.
Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison W; Rabkin JG; Tricamo E; Markowitz JS; Klein DF
J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):22-5. PubMed ID: 6376483
[TBL] [Abstract][Full Text] [Related]
5. Haloperidol vs. phenelzine in continuation therapy of borderline disorder.
Cornelius JR; Soloff PH; George A; Ulrich RF; Perel JM
Psychopharmacol Bull; 1993; 29(2):333-7. PubMed ID: 8290683
[TBL] [Abstract][Full Text] [Related]
6. Chronic depression: response to placebo, imipramine, and phenelzine.
Stewart JW; McGrath PJ; Quitkin FM; Rabkin JG; Harrison W; Wager S; Nunes E; Ocepek-Welikson K; Tricamo E
J Clin Psychopharmacol; 1993 Dec; 13(6):391-6. PubMed ID: 8120152
[TBL] [Abstract][Full Text] [Related]
7. Defining the boundaries of atypical depression.
Quitkin FM; Harrison W; Liebowitz M; McGrath P; Rabkin JG; Stewart J; Markowitz J
J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):19-21. PubMed ID: 6376482
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of phenelzine and haloperidol in borderline personality disorder.
Soloff PH; Cornelius J; George A; Nathan S; Perel JM; Ulrich RF
Arch Gen Psychiatry; 1993 May; 50(5):377-85. PubMed ID: 8489326
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of symptoms of atypical depression for differential drug treatment outcome.
McGrath PJ; Stewart JW; Harrison WM; Ocepek-Welikson K; Rabkin JG; Nunes EN; Wager SG; Tricamo E; Quitkin FM; Klein DF
J Clin Psychopharmacol; 1992 Jun; 12(3):197-202. PubMed ID: 1629387
[TBL] [Abstract][Full Text] [Related]
10. Phenelzine for chronic depression: a study of continuation treatment.
Harrison W; Rabkin J; Stewart JW; McGrath PJ; Tricamo E; Quitkin F
J Clin Psychiatry; 1986 Jul; 47(7):346-9. PubMed ID: 3522558
[TBL] [Abstract][Full Text] [Related]
11. Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors.
Thase ME; Frank E; Mallinger AG; Hamer T; Kupfer DJ
J Clin Psychiatry; 1992 Jan; 53(1):5-11. PubMed ID: 1737741
[TBL] [Abstract][Full Text] [Related]
12. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine.
Cornelius JR; Soloff PH; Perel JM; Ulrich RF
Am J Psychiatry; 1993 Dec; 150(12):1843-8. PubMed ID: 8238640
[TBL] [Abstract][Full Text] [Related]
13. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders.
Quitkin FM; Stewart JW; McGrath PJ; Liebowitz MR; Harrison WM; Tricamo E; Klein DF; Rabkin JG; Markowitz JS; Wager SG
Am J Psychiatry; 1988 Mar; 145(3):306-11. PubMed ID: 3278631
[TBL] [Abstract][Full Text] [Related]
14. Treatment response of depressed outpatients unresponsive to both a tricyclic and a monoamine oxidase inhibitor antidepressant.
McGrath PJ; Stewart JW; Nunes EN; Quitkin FM
J Clin Psychiatry; 1994 Aug; 55(8):336-9. PubMed ID: 8071301
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression.
Agosti V; Stewart JW
Int Clin Psychopharmacol; 2007 Sep; 22(5):309-11. PubMed ID: 17690600
[TBL] [Abstract][Full Text] [Related]
16. Antidepressant specificity in atypical depression.
Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison WM; Markowitz JS; Rabkin JG; Tricamo E; Goetz DM; Klein DF
Arch Gen Psychiatry; 1988 Feb; 45(2):129-37. PubMed ID: 3276282
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of imipramine and phenelzine on corticosteroid receptor gene expression in mouse brain: potential relevance to antidepressant response.
Heydendael W; Jacobson L
Brain Res; 2008 Oct; 1238():93-107. PubMed ID: 18761333
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission.
Stewart JW; Tricamo E; McGrath PJ; Quitkin FM
Am J Psychiatry; 1997 Jan; 154(1):31-6. PubMed ID: 8988955
[TBL] [Abstract][Full Text] [Related]
19. Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression.
Quitkin FM; McGrath PJ; Stewart JW; Harrison W; Wager SG; Nunes E; Rabkin JG; Tricamo E; Markowitz J; Klein DF
Arch Gen Psychiatry; 1989 Sep; 46(9):787-93. PubMed ID: 2673130
[TBL] [Abstract][Full Text] [Related]
20. Phenelzine v imipramine in atypical depression. A preliminary report.
Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison W; Rabkin J; Tricamo E; Markowitz JS; Klein DF
Arch Gen Psychiatry; 1984 Jul; 41(7):669-77. PubMed ID: 6375621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
